Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Drugs Made In America Acquisition (DMAA) Equity Average (2025)

Drugs Made In America Acquisition filings provide 1 years of Equity Average readings, the most recent being -$7.3 million for Q4 2025.

  • Quarterly Equity Average changed N/A to -$7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$3.8 million for FY2025, N/A changed from the prior year.
  • Equity Average hit -$7.3 million in Q4 2025 for Drugs Made In America Acquisition, down from -$7.2 million in the prior quarter.
  • Across five years, Equity Average topped out at -$3.7 million in Q1 2025 and bottomed at -$7.3 million in Q4 2025.